Galapagos NV Stock price

Equities

GLPG

BE0003818359

Biotechnology & Medical Research

Market Closed - Euronext Amsterdam 11:35:11 2024-03-04 am EST Pre-market 02:54:11 am
32.07 EUR -0.71% Intraday chart for Galapagos NV 32.24 +0.51%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Enjoy this offer
* See conditions on site
Sales 2023 784M 850M Sales 2024 * 421M 456M Capitalization 2.11B 2.29B
Net income 2023 212M 230M Net income 2024 * -60M -65.07M EV / Sales 2023 3.11 x
Net cash position 2023 * 3.62B 3.92B Net cash position 2024 * 3.35B 3.63B EV / Sales 2024 * -2.93 x
P/E ratio 2023
11.5 x
P/E ratio 2024 *
-45.6 x
Employees 1,338
Yield 2023 *
-
Yield 2024 *
-
Free-Float 74.6%
More Fundamentals * Assessed data
Dynamic Chart
Galapagos to Seek Acquisitions CI
Transcript : Galapagos NV, 2023 Earnings Call, Feb 23, 2024
Frontier Medicines Corporation announced that it has received $80 million in funding from Deerfield Management Company, L.P. Series C, DROIA nv, Galapagos NV, DCVC, MPM Asset Management, L.L.C., RA Capital Management, L.P. and other investors CI
Galapagos NV Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Galapagos NV to Present New Preliminary Translational Data at EBMT-EHA Annual Meeting 2024 CI
Galapagos Completes Sale of Jyseleca Business to Alfasigma MT
Alfasigma S.p.A. completed the acquisition of Filgotinib business from Galapagos NV. CI
Galapagos NV Enters into Strategic Collaboration Agreement with Thermo Fisher Scientific, Inc. to Further Expand Its Decentralized CAR-T Manufacturing Network in the U.S CI
Galapagos Partners with Thermo Fisher for Manufacturing in US MT
Galapagos, Thermo Fisher Scientific to Establish Decentralized CAR-T Manufacturing Network MT
Galapagos, Thermo Fisher to Collaborate on Expanding Manufacturing of Cancer Drug DJ
Galapagos, BridGene Biosciences Partner to Develop New Medicines for Oncology Targets MT
Galapagos to Collaborate With BridGene to Discover, Develop New Medicines for Oncology Targets MT
BridGene Biosciences, Inc. Announces Strategic Collaboration and Licensing Agreement with Galapagos NV CI
Global markets live: HSBC, Baidu, Exxon Mobil, Geely, Tesla... Our Logo
More news
1 day-0.71%
1 week-5.62%
Current month-2.49%
1 month-7.15%
3 months-9.94%
6 months-8.19%
Current year-13.30%
More quotes
1 week
31.80
Extreme 31.8
34.22
1 month
31.80
Extreme 31.8
37.17
Current year
31.80
Extreme 31.8
39.00
1 year
30.11
Extreme 30.11
41.92
3 years
30.11
Extreme 30.11
71.82
5 years
30.11
Extreme 30.11
252.90
10 years
10.00
Extreme 10
252.90
More quotes
Managers TitleAgeSince
Chief Executive Officer 62 22-03-31
Director of Finance/CFO 54 23-06-30
Investor Relations Contact - 20-10-31
Members of the board TitleAgeSince
Director/Board Member 66 22-04-25
Director/Board Member 65 23-09-18
Director/Board Member 61 19-10-21
More insiders
Date Price Change Volume
24-03-04 32.07 -0.71% 118,155
24-03-01 32.3 -1.79% 121,102
24-02-29 32.89 -2.40% 131,498
24-02-28 33.7 -1.03% 70,918
24-02-27 34.05 +0.21% 87,640

Real-time Euronext Amsterdam, March 04, 2024 at 11:35 am EST

More quotes
Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing innovative medicines. The company is committed to improving patients' lives worldwide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
10
Last Close Price
32.07 EUR
Average target price
39.53 EUR
Spread / Average Target
+23.26%
Consensus
  1. Stock
  2. Equities
  3. Stock Galapagos NV - Euronext Amsterdam
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW